VivoSeq
Oncology

NSCLC (non-Small Cell Lung Cancer)

5

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

NSCLC (Non-small Cell Lung Cancer) is an early-stage landscape with 5 programs across 4 companies. The most active players are BeiGene, Revolution Medicines, Avyxa. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BeiGene logo

BeiGene

1 program

Phase 2Revolution Medicines logo

Revolution Medicines

1 program

Phase 3A

Avyxa

1 program

Phase 3E

Elephas

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 80% of 5 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
Recruiting·Revolution Medicines logoRevolution Medicines·Phase 3·NCT06881784·590 enrolled
A Randomized Phase 2 Study of Hypofractionated Concurrent Chemoradiotherapy Combined With Tislelizumab and Surufatinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Recruiting·SSun Yat-sen University·Phase 2·NCT07609121·160 enrolled
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)
Active, not recruiting·EElephas·N/A·NCT05478538·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)